XML 84 R18.htm IDEA: XBRL DOCUMENT
v3.19.3

Earnings (Loss) Per Share | 9 Months Ended
--- | ---
Sep. 30, 2019
Earnings Per Share [Abstract] |
Earnings (Loss) Per Share | Earnings (Loss) Per Share Earnings (loss) per share is computed using the two-class method. For periods in which the Company reports net income, diluted earnings per share is determined by using the weighted average number of common and dilutive common equivalent shares outstanding during the period, unless the effect is antidilutive. Stock appreciation rights and options to purchase 18 million and 19 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share, for the three and nine months ended September 30, 2019, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, options to purchase 12 million and 14 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share, for the three and nine months ended September 30, 2018, respectively. Due to the loss from continuing operations attributable to CVS Health in the nine months ended September 30, 2018, 2 million potentially dilutive common equivalent shares also were excluded from the calculation of diluted earnings per share, as the impact of these shares was antidilutive. The following is a reconciliation of basic and diluted earnings (loss) per share from continuing operations for the respective periods:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
In millions, except per share amounts | 2019 |  | 2018 |  | 2019 |  | 2018
Numerator for earnings (loss) per share calculation: |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | 1,529 |  |  | $ | 1,390 |  |  | $ | 4,887 |  |  | $ | (174 | )
Income from continuing operations allocated to participating securities | — |  |  | (1 | ) |  | (3 | ) |  | (3 | )
Loss from continuing operations attributable to noncontrolling interest | 1 |  |  | — |  |  | — |  |  | — |
Income (loss) from continuing operations attributable to CVS Health | $ | 1,530 |  |  | $ | 1,389 |  |  | $ | 4,884 |  |  | $ | (177 | )
Denominator for earnings (loss) per share calculation: |  |  |  |  |  |  |
Weighted average shares, basic | 1,302 |  |  | 1,020 |  |  | 1,300 |  |  | 1,018 |
Effect of dilutive securities | 3 |  |  | 2 |  |  | 3 |  |  | — |
Weighted average shares, diluted | 1,305 |  |  | 1,022 |  |  | 1,303 |  |  | 1,018 |
Earnings (loss) per share from continuing operations: |  |  |  |  |  |  |
Basic | $ | 1.17 |  |  | $ | 1.36 |  |  | $ | 3.76 |  |  | $ | (0.17 | )
Diluted | $ | 1.17 |  |  | $ | 1.36 |  |  | $ | 3.75 |  |  | $ | (0.17 | )

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration